Human metapneumovirus (HMPV) is a respiratory virus that was first discovered in 2001, although retrospective studies suggest it had been circulating undetected for decades. It primarily affects the respiratory tract, causing symptoms that range from mild cold-like presentations to more severe complications such as bronchiolitis and pneumonia. Below are five key facts to help you understand HMPV and its impact on human health.
1. A Relatively Recent Discovery
HMPV was first isolated in 2001 by Dutch researchers who identified a new viral agent in young children with respiratory infections. It belongs to the Pneumoviridae family and is closely related to respiratory syncytial virus (RSV). Retrospective studies indicate that HMPV had been circulating undetected in humans for decades before its official discovery.
2. Who Is Most at Risk?
While HMPV can infect people of all ages, infants, young children, older adults, and immunocompromised individuals are more likely to experience severe complications. In healthy adults, symptoms often resemble a common cold, but in vulnerable populations, the virus can progress to bronchiolitis, pneumonia, and other lower respiratory tract issues.
3. Transmission and Seasonality
Like RSV and influenza, HMPV spreads primarily through respiratory droplets (coughing, sneezing) or contact with contaminated surfaces. In temperate regions, HMPV infections typically peak during late winter or early spring—concurrent with seasonal surges of other respiratory viruses.
4. Symptoms and Clinical Presentation
Common symptoms include cough, runny nose, nasal congestion, sore throat, wheezing, and fever. In high-risk groups, more severe signs such as difficulty breathing, rapid breathing, and respiratory distress may occur, potentially requiring hospitalization.
5. Treatment and Prevention Efforts
Currently, there is no specific antiviral therapy or approved vaccine for HMPV. Treatment focuses on supportive measures: rest, hydration, fever management, and oxygen therapy if needed. Researchers are exploring vaccine candidates and antiviral medications, but these remain in clinical or preclinical stages of development.
Rate of Infections in the United States
• General Positivity Rate: According to CDC surveillance data from recent respiratory virus seasons, the HMPV test positivity rate has at times reached around 10–11% of sampled specimens during its seasonal peak (late winter to spring). This rate can vary year to year and by region.
• Annual Fluctuations: HMPV circulates similarly to other seasonal viruses, so its exact prevalence can rise or fall based on factors like local outbreaks, testing availability, and public health measures.
Top 5 States with Higher Positivity Rates
While comprehensive, real-time state-by-state HMPV data can be limited, public health records and surveillance reports often show that larger or more densely populated states detect higher numbers of respiratory infections overall—simply because there are more tests conducted and larger populations at risk. In recent seasons, Florida, Texas, California, New York, and Georgia have often reported elevated HMPV activity or positivity rates. Reasons include:
1. High Population Density: More people living in close quarters can enhance viral transmission.
2. Travel Hubs: States with major international airports see higher disease importation and spread.
3. Testing Capacity: Greater healthcare infrastructure and testing resources can capture more confirmed cases.
4. Seasonal Climate Patterns: Warmer climates in states like Florida and Texas can alter the timing and spread of respiratory infections.
5. Demographic Factors: Larger elderly populations in states like Florida may also drive up reported severe cases.
Selected Research and References
1. Van den Hoogen BG, et al. (2001).
A newly discovered human pneumovirus isolated from young children with respiratory tract disease.
Nature Medicine, 7(6), 719–724.
– Landmark paper describing the initial discovery of HMPV in pediatric patients.
2. Boivin G, et al. (2002).
Human Metapneumovirus Infections in Hospitalized Children.
Emerging Infectious Diseases, 8(9), 979–982.
– Early study detailing clinical impact of HMPV in children.
3. Williams JV. (2013).
The clinical and molecular epidemiology of human metapneumovirus.
The Pediatric Infectious Disease Journal, 32(8), 907–908.
– Discusses prevalence, clinical manifestations, and molecular characteristics of HMPV.
4. Panda S, Mohakud NK, Pena L, Kumar S. (2014).
Human metapneumovirus: review of an important respiratory pathogen.
Indian Journal of Medical Microbiology, 32(3), 265–275.
– Comprehensive review summarizing pathogenesis, diagnosis, and prevention strategies.
5. CDC – Human Metapneumovirus (HMPV).
Centers for Disease Control and Prevention Website.
– Offers updated information, including surveillance data and recommendations for clinicians.
Although much progress has been made in characterizing human metapneumovirus, further surveillance and research are needed to develop effective vaccines and targeted therapies—particularly for those populations most susceptible to severe disease.
To read more about HMPV, visit CDC
Read more about Primary Telecare
